Analysis of Mutations in the Plasma Cholinesterase Gene of Patients with a History of Prolonged Neuromuscular Block during Anesthesia

Barta, Csaba; Sasvári-Székely, Mária; Devai, Adrien; Kovács, Enikő; Staub, Maria; Enyedi, Péter

doi:10.1006/mgme.2001.3251

Cited by 21 publications

(11 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…malignant hyperthermia [14] or pseudocholinesterase deficiency [15]), anaesthetists are applying this line of thinking to study of the possible role of specific alleles in cardiovascular [16] and cerebral [17] outcomes after surgery, clotting postsurgery [18], renal function [19] and even less 'dramatic' issues such as the effectiveness of topical anaesthesia creams [20].…”

Section: Relevance For Clinical Anaesthesiamentioning

confidence: 99%

‘Hardy’s Law’ and genomics in Anaesthesia

Pandit

2008

Anaesthesia

View full text Add to dashboard Cite

Section: Relevance For Clinical Anaesthesiamentioning

confidence: 99%

‘Hardy’s Law’ and genomics in Anaesthesia

Pandit

2008

Anaesthesia

View full text Add to dashboard Cite

“…Both genetic and environmentally induced variability in the function of plasma cholinesterase (butyrylcholinesterase, BuChE) can extend the duration of suxamethonium‐induced block for minutes to hours (54,55). Some genetic variations in BuChE may not be found by standard biochemical tests (56,57). Age‐related variation in BuChE results can complicate interpretation of the results (58).…”

Section: Hyperkalemiamentioning

confidence: 99%

The place of suxamethonium in pediatric anesthesia

Rawicz

Brandom

Wolf

2009

Pediatric Anesthesia

View full text Add to dashboard Cite

Summary Suxamethonium is a drug that promotes very strong views both for and against its use in the context of pediatric anesthesia. As such, the continuing debate is an excellent topic for a ‘Pro–Con’ debate. Despite ongoing efforts by drug companies, the popular view still remains that there is no single neuromuscular blocking drug that can match suxamethonium in terms of speed of onset of neuromuscular block and return of neuromuscular control. However, with this drug the balance of benefit vs risk and side effects are pivotal. Suxamethonium has significant adverse effects, some of which can be life threatening. This is particularly relevant for pediatric anesthesia because the spectrum of childhood diseases may expose susceptible individuals to an increased likelihood of adverse events compared with adults. Additionally, the concerns related to airway control in the infant may encourage the occasional pediatric anesthetist to use the drug in preference to slower onset/offset drugs. In the current environment of drug research, surveillance and licensing, it is debatable whether this drug would achieve the central place it still has in pediatric anesthesia. The arguments for and against its use are set out below by our two international experts, Marcin Rawicz from Poland and Barbara Brandom from USA. This will allow the reader an objective evaluation with which to make an informed choice about the use of suxamethonium in their practice.

show abstract

“…All four exons of the BCHE gene were amplified by five primer sets [6][7][8], which were for exon 1, for the 5 0 half of exon 2, for the 3 0 half of exon 2, for exon 3 and for exon 4 using TaKaRa Taq (TAKARA BIO INC.) for direct sequencing. After confirmation of PCR products by 1.5% agarose gel, these were purified by Microcon YM-100 (Millipore Corporation) and examined as to the quality and quantity of the product by absorbance assay.…”

Section: Casementioning

confidence: 99%